Akesobio
康方生物科技(開曼)有限公司
(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)
Stock Code 股份代號：9926

Akeso in 2023 and Beyond

Global Biopharma Innovator with Competitive Advantage in Oncology and beyond

J.P.Morgan 42nd Annual Healthcare Conference, 9 January 2024

Michelle Xia, Ph.D, Founder, Chairwoman & CEO

Disclaimer

This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase securities of Akeso, Inc. (the “Company”).

This presentation does not constitute or contain an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in any jurisdiction in which the making of such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction, and neither this presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

All the information in this presentation has been provided by the Company and has not been independently verified by its advisers or any of their respective affiliates or associates (collectively, "advisers"). No representation, warranty or undertaking, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company or any of its subsidiaries or by its advisers or representatives as to the fairness, accuracy, completeness or correctness of, this presentation or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as “will”, “expects”, “believes” and "anticipates" and words of similar import. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company and its advisers or representatives are unaware. These forward-looking statements are not a guarantee of future performance. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation is confidential and must not be copied, reproduced, distributed or passed (in whole or in part) to any other person at any time without the prior written consent of the Company or its advisers.

By accepting this presentation, the recipient has agreed, upon request, to return promptly all material received from the Company or its advisers (including this presentation) without retaining any copies. In furnishing this presentation, the Company and its advisers or representatives undertake no obligation to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies therein which may become apparent.

The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or under the laws of any state of the United States. This presentation is directed only at (1) “qualified institutional buyers" as defined in the U.S. Securities Act within the U.S. or (2) any person outside the U.S. and, in addition, persons which are lawfully able to receive this presentation under the laws of the jurisdictions in which they are located or other applicable laws (“relevant persons”), including but not limited to professional investor (as such term is defined in the Securities and Futures Ordinance (Cap. 571)). This presentation does not constitute or form a part of and should not be construed as any offer to sell or issue or solicitation to purchase or subscribe for securities in the United States. The securities of the Company will not be offered or sold in the United States except in certain transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the Company and its management and financial statements. There will be no public offer of the Company's securities in the United States. Any investment or investment activity to which this presentation relates are available only to relevant persons and will be engaged in only with relevant persons. By accepting this presentation the recipient represents and warrants that (a) it is lawfully able to receive this presentation under the laws of the jurisdiction in which it is located or other applicable laws; (b) it is either a “qualified institutional buyer” or located outside the United States, and (c) it will not reproduce, publish, disclose, redistribute or transmit this presentation, directly or indirectly, either within or outside of the recipient’s organization.

The distribution of this presentation in any jurisdiction may be restricted by law and persons in possession of this presentation should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

Any prospective purchaser interested in buying securities of or evaluating the Company is recommended to seek its own independent legal, tax, financial and other professional advice.

The Akeso Story

Founded in 2012
by a group of top dedicated scientists formerly working at global pharmaceutical companies
- Driven to discover and develop first-in-class and best-in-class medicines

Listed in HKEX since 2020 (09926.HK)
Market Cap: 39B HKD (~ 5B USD) as 29 December 2023
Leading biopharma company in China

Our Vision is to use the power of science and technology to develop new medicines for global patients

100%
Fully integrated in-house drug discovery, CMC, GMP manufacturing, clinical development and commercialization (bispecific mAb, ADC, bispecific ADC, cell therapy etc.)

- **TETRABODY**: Our proprietary bispecific mAb technology – create the bispecific from asymmetric bivalent form into tetravalent structure
  - Developed bispecific mAbs with tetravalent design to achieve efficacy while lower toxicities
  - Our global first marketed PD-1 based bispecific mAb proved more powerful than PD-(L)1 mAb for combination therapies

Akeso Today (at a Glance in Jan 2024) – Solid Foundation for Continued Growth

3
Commercial drugs in China (1 out-licensed)
World's 1st marketed dual checkpoint blocking bispecific (Cadonilimab)

50+
Innovative assets, covering oncology, immunology, CNS and metabolic diseases

5.39 B (RMB) ($800M+)
- Cash balance as 2023.6.30
- Well capitalized and on path to profitability

9
NDA/sNDA filed (5 new products)
Potentially world's 1st marketed checkpoint /angiogenesis bispecific (Ivonescimab)

19
Clinical-stage pipeline

2,800+ Akeso team
- 1100+ R&D
- 650+ manufacturing
- 800+ commercial

6
Bispecific mAbs in clinical stages
- 1 commercial - Cadonilimab
- 1 filed for NDA - Ivonescimab

120+
Ongoing clinical trials

55.5-acre
- Self-owned R&D and biologics manufacturing sites
- Current biologics production capacity: 54,000L

- Cadonilimab: FIC bispecific mAb targeting on two I/O checkpoint proteins (PD-1 and CTLA-4), approved for marketing in China
- Ivonescimab: FIC bispecific mAb targeting on I/O and angiogenesis proteins (PD-1 and VEGF), filed for marketing approval

Akeso Innovation Highlights: Leader in Bispecific Antibody Research & Development

- **Akeso expanded the bispecific antibody world from asymmetric bivalent form into tetravalent structure, well suited for target enriched situation like the tumor microenvironment (TME)**



- **Delivery of Safety and Efficacy:**

  Clinical POC with Cadonilimab (PD-1/CTLA-4) and Ivonescimab (PD1/VEGF), e.g.

  - Bleeding risk is significantly reduced with patients treated by ivonescimab vs. bevacizumab
  - Use of ivonescimab in previously impossible indications for VEGF blockers like sq NSCLC

Squamous NSCLC	Ivonescimab (N=122)	Bevacizumab
≥ grade3 Hemoptysis/pulmonary hemorrhage	1.6%[1]	31%[2]

1: Data from clinical trials AK112-201 and AK112-202 Median follow up: 18.6 months (Data cutoff: June 30, 2023)

2: Data from bevacizumab label

Akeso Innovation Highlights: Safe Bispecifics as Cornerstone Drugs to Enable Additional Combination for Deeper Efficacy

Tumor Immunotherapy Combinations



- ✓ With proved safety and efficacy as monotherapy, cadonilimab and ivonescimab, the two cornerstone drugs, serving as foundations of combination therapies, to improve the overall efficacy
- ✓ Complemented by a broad portfolio of products targeting key links in the tumor immune circuit – TIGIT, CD47, CD73, VEGFR2, PD-1/LAG3, TIGIT/ TGFβ, Claudin18.2/CD47 …

Cadonilimab / Ivonescimab

Cornerstone Bispecific mAbs for Combination Therapies (with new direction, new mechanism, new pipeline etc)

+ Check-point Inhibitor	+ Targeted Therapy	+ ADC	+ New MOA

- ❑ Multiple Phase Ib/II trials are ongoing at Akeso to evaluate the potentially deeper efficacy through combination with bispecific antibodies
- ❑ Promising efficacy and safety results obtained in the trials, and data planned to be published in 2024

e.g.

- Cadonilimab+pulocimab (AK109)+chemo in 2L IO resistant GC/GEJC (AK109-201)
- Cadonilimab+TACE+Lenvatinib in unresectable HCC (AK104-216) – ASCO GI (2024)
- Ivonescimab+ligufalimab in 1L PD-1(+) HNSCC (AK117-201)

Akeso Innovation Highlights: Expand & Extend to Deliver Bispecific Technologies to More Patients



Commercialized	Cadonilimab PD-1/CTLA4	• Dual immune checkpoint bispecific antibodies
NDA Applied	Ivonescimab PD-1/VEGF	• Targets highly co-expressed in TME
Phase I	PD-1/CD73	• Immune checkpoint/ immune suppressor bi-specific antibodies
Phase I	PD-1/LAG3	• High expression of both targets in TME
Phase II	TIGIT/TGFβ	
Phase I	CLDN18.2/CD47	• Asymmetric bivalent bsAb

Multiple PD-1-based bispecific molecules covering a diverse landscape of immuno-suppression
Advanced combo strategies centered around bispecific with targeted or chemotherapy

Akesobio



Cadonilimab

First Marketed Dual Checkpoint Blocking Antibody Targeting PD-1 & CTLA-4

Design of Tetravalent Bispecific Antibody to Deliver Better Efficacy and Safety – Cadonilimab (AK104)

Globally First Approved tetravalent bispecific antibody

Bivalent design



Target enrichment in TME

Tetravalent design



Anti-PD-1

Fc region

Anti-CTLA-4

Cadonilimab (AK104)



AK104 with more potent binding activity than AK105 to a high density of PD1 and CTLA-4

Comparable binding activity of AK104 and AK105 to a low density of PD1

Fixed antigens (nM)		Antibody	KD (M)	kon(1/Ms)	kdis(1/s)
PD1-mFc CTLA4mFc	50	**AK104**	**3.69E-11**	**1.06E+06**	**3.92E-05**
		AK105	1.98E-10	1.18E+06	2.33E-04
PD1-mFc	10	**AK104**	**3.48E-10**	**1.44E+06**	**5.01E-04**
		AK105	3.58E-10	1.22E+06	4.36E-04

- PD-1 and CTLA-4 featured high level co-expression in tumor (TILs and nodes), and low single expression in peripheral normal tissue
- Tetravalent design allows higher avidity binding in target enriched TME, as supported by the binding assays

(AK105: anti-PD-1 antibody penpulimab)



- Cadonilimab shows stronger tumor retention compared to anti-PD-1 or anti-CTLA-4 antibody in the radioisotope labeling study

Published on mAbs,2023,VOL.15,NO.1,2180794

Cadonilimab Global Clinical Trials

Field	Treatment	Indications		Phase I	Phase II	Phase III	NDA submission/ Approval
Cervical cancer	Mono	2L/3L Cervical Cancer					Approved in 2022
	+ chemotherapy ± bevacizumab	1L Cervical cancer				Primary endpoint met	
	Mono	Neoadjuvant therapy for cervical cancer					
Gastric cancer	+ XELOX chemotherapy	1L GC/GE					NDA submitted
	+AK109 (VEGFR2)+ chemotherapy	2L GC/GEJ (PD-1/L1 relapse/refractory)					
	+AK117+chemotherapy	1L GC/GEJ					
	±AK117+ chemotherapy	Neoadjuvant therapy for GC/GEJ					
Hepatocellular carcinoma	Mono	Adjuvant therapy for HCC				Enrollment ongoing	
	+ Lenvatinib	1L HCC					
	+ Lenvatinib+TACE	intermediate unresectable HCC					
	+AK109	2L HCC (PD-1/L1 relapse/refractory)					
Lung cancer	+ Chemotherapy	1L PD-L1 negative NSCLC				Enrollment ongoing	
	+ Chiauranib	≥2L SCLC					
	+ Docetaxel	2L r/r NSCLC					
	+AK109±docetaxel	2L NSCLC (PD-1/L1 relapse/refractory)					
	+AK112 ± chemotherapy	advanced non-small cell lung cancer					
ESCC*	± AK117+ chemotherapy	1L ESCC					
Pancreatic cancer	+ Chemotherapy	1L PDAC					
Others	+AK117 (CD47)	advanced solid tumor					
	+AK119 (CD73)	advanced solid tumor					
	+AK127 (TIGIT)	advanced solid tumor					

Selective disclosure of ongoing clinical trials
**ESCC: esophageal squamous cell carcinoma*

global trial
approved
registrational clinical trials

2,500+ Patients Treated with Cadonilimab across all trials to date
22+ Clinical Trials with 5 Phase III/Pivotal

Candolimab Phase III Trials – Expected Short-Term Catalysts

AK104-307
First Patient In
1L PD-L1(-) NSCLC Ph III**

Participate in Major Medical Conferences

AK104-302 (1L GC/GEJC) and AK104-303 (1L CC) Data Readout

Q1 2024	Q2 2024	Q3 2024	Q4 2024

AK104-302
sNDA Filing*
1L GC/GEJC Ph III

AK104-303
sNDA Filing*
1L CC Ph III

AK104-306
Last Patient In
Adjuvant HCC Ph III

**NDA Filing with the CDE for Marketing Approval in China*
***Head-to-Head vs. Tislelizumab*

Approved in China for 2/3L recurrent and metastatic cervical cancer to the market in June 2022

- **Cumulative sales of the first 12 months (2022H2 - 2023H1): 1.15B RMB ($165M)**

Akesobio



Ivonescimab

Potential FIC PD-1/ VEGF Bispecific Antibody

NDA submitted

Tetravalent Bispecific Antibody to Deliver Better Efficacy and Safety – Ivonescimab (AK112)

Partnership with Aligned Mission
- Licensing of Ivonescimab to Summit Therapeutics

$500M
Upfront received

$5B
Total milestones

Low double - digit
Royalties of net sales

- $500M upfront was received in full
- 2 global Ph III studies initiated

Record-breaking licensing volume for innovative drugs originated in China

依达方®
Ivonescimab
(PD-1/VEGF, AK112/SMT-112)

- Exclusive licensing of development & commercialization to Summit in US, Canada, Europe, and Japan
- Accelerating the process to bring ivonescimab to patients around the world

Ivonescimab Global Oncology Clinical Trials

Summit therapeutics

Trial	Indication	Histology/Population	Regimen	Phase III
★ HARMONi	NSCLC	**EGFRm+** 2L+ Advanced or Metastatic	Combo ivonescimab + chemo vs. placebo + chemo	
★ HARMONi-3	NSCLC	**Squamous** 1L Metastatic	Combo ivonescimab + chemo vs. pembro + chemo	

Akesobio

Indication	Regimen	Phase I	Phase II	Phase III
★ NSCLC: 2L EGFRm+	Randomized: Combo (chemo) vs. chemo			
NSCLC: 1L PD-L1 TPS>1%	Randomized: Monotherapy vs. pembro (PD-1)			
★ NSCLC: 1L Squamous	Randomized: Combo (chemo) vs. tislelizumab (PD-1) + chemo			
NSCLC: 1L Squamous	Randomized: Combo (chemo) vs. pembro (PD-1) + chemo			
Advanced Solid Tumors	Monotherapy			
NSCLC	Combo (chemo)			
NSCLC	Monotherapy			
GYN Tumors	Monotherapy			
Ovarian Cancer	Combination (PARPi)			
NSCLC	Monotherapy & Combo (chemo)			
CRC	Combo (CD47 + chemo)			
HCC	Monotherapy			
NSCLC	Combo (PD-1 / CTLA-4 bsAb + chemo)			
HNSCC	Combo (CD47)			
Advanced Solid Tumors**	Combo (CD47, CD47 + chemo, chemo)			
TNBC	Comb (chemo, CD47 + chemo)			
NSCLC	Combo (CD73 + chemo)			
Advanced Solid Tumors	Monotherapy			
ES-SCLC	Combo (chemo)			

1,600+ Patients treated with ivonescimab across all trials to date

19+ Clinical Trials With 4 Phase III

These ivonescimab clinical trials are being conducted in China and/or Australia and are fully sponsored and managed by Akeso.

NSCLC: Non-Small-cell Lung Cancer, EGFRm+: Epidermal Growth Factor Receptor mutant positives, Combo: Combination, Chemo: Chemotherapy, pembro: pembrolizumab, CRC: Colorectal Cancer, HCC: Hepatocellular Carcinoma, HNSCC: Head & Neck Squamous Cell Carcinoma, BTC: Biliary Tract Cancer, TNBC: Triple Negative Breast Cancer, ES-SCLC: Extensive Stage Small Cell Lung Cancer, PD-1: Programmed Cell Death Protein 1, PARPi: poly(ADP-ribose) polymerase inhibitors
**Includes Gastric, BTC, Pancreatic, NSCLC

★ Same Subset Patient Population

★ Same Subset Patient Population

Ivonescimab NDA Filed in China, Global Phase III Trials Initiated

Ivonescimab
(PD-1/VEGF, AK112/SMT-112）

AK112-301

EGFR-TKI progressor of locally advanced or metastatic nsqNSCLC

- ✓ **1st indication in China**
- ✓ **NDA accepted by** CDE in August 2023 under **priority review**

AK112-303

- ✓ 1L PD-L1+ NSCLC

(mono vs. pembrolizumab) **enrollment completed**

AK112-306

- ✓ 1L locally advanced or metastatic sq-NSCLC **enrollment ongoing**

(AK112+chemo *vs.* tislelizumab +chemo)

HARMONi/AK112-301

3rd gen EGFR-TKI progressor of locally advanced or metastatic nsqNSCLC global Phase III:

- ✓ **Enrollment ongoing in US and Europe**
- ✓ Enrollment completed for Chinese part (AK112-301)

HARMONi-3/AK112-3003

1L metastatic sq-NSCLC global Phase III:

- ✓ **Enrollment ongoing globally**

（SMT-112+chemo *vs. pembrolizumab*+chemo）

1L Adv/Metastatic Squamous NSCLC[1,2]

Phase II Ivonescimab + Chemo

Median follow up 21.0 months (DCO: 10/10/23)



*includes subjects with at least one post-baseline tumor assessment

Percent Changes from Baseline in Target Lesions
Sum of Diameters (N=60)

Presentation exclusively for purposes of evaluating the landscape for ivonescimab

AK112-201 includes 10 mg/kg dosing (16%) and 20 mg/kg dosing (84%) of ivonescimab

	AK112-201 Cohort 1: SQ only; ivonescimab + chemo Phase II, N=63
ORR†	67%
DCR†	95%
mDOR†	12.8m
mPFS [95% CI]	11.1m [9.5 – 16.3]

Established Standard of Care

	KEYNOTE-407 China Extension[3] pembrolizumab + chemo; randomized Phase III, N=65	KEYNOTE-407 Global[4] pembrolizumab + chemo; randomized Phase III, N=278
ORR†	80%	63%
DCR†	91%	86%
mDOR	7.1m	8.8m
mPFS [95% CI]	8.3m [6.2 – 10.5]	8.0m [6.3 – 8.4]

ORR: Overall Response Rate, mDOR: median Duration of Response, mPFS: median Progression Free Survival, DCO: data cutoff, NSCLC: Non-small Cell Lung Cancer, 1L: First Line, CI: Confidence Interval, SQ: Squamous, mFU: median follow-up, chemo: chemotherapy, m: month

† *Includes subjects with at least one post-baseline tumor assessment, ORR based on confirmed BOR; N=60 evaluable for response*

1. Zhang L, et al., ASCO 2023 poster #9087; 2. Data on File, Akeso Inc; 3.Cheng et. al. *JTO Clin Res Rep* (2021) ; 4.Paz-Ares, et. al. *Journal of Thoracic Onc* (2020)

1L Adv/Metastatic Squamous NSCLC[1,2]

Phase II Ivonescimab + Chemo

Median follow up 21.0 months (DCO: 10/10/23)



Presentation exclusively for purposes of evaluating the landscape for ivonescimab

AK112-201 includes 10 mg/kg dosing (16%) and 20 mg/kg dosing (84%) of ivonescimab

Established Standard of Care

	AK112-201 Cohort 1: SQ only ivonescimab + chemo Phase II, N=63	KEYNOTE-407 China Extension[3] pembrolizumab + chemo; randomized Phase III, N=65	KEYNOTE-407 Global[4] pembrolizumab + chemo; randomized Phase III, N=278
mOS	**Not Reached** [22.5 – NE]	**30.1m** [18.2 – NR]	**17.2m** [14.4 – 19.7)
12m OS	**85.6%**	**78.5%**	**64.7%**
24m OS	**64.8%**	**56.9%**	**36.0%**

OS: overall survival, DCO: data cutoff NSCLC: Non-small Cell Lung Cancer, 1L: First Line, CI: Confidence Interval, SQ: Squamous, pembro: pembrolizumab, chemo: chemotherapy, NE: Not Established, NR Not Reached, TRAEs: Treatment Related Adverse Events

1. Zhang L, et al., ASCO 2023 poster #9087; 2. Data on File, Akeso Inc; 3. Cheng, et. al. *JTO Clin Res Rep* (2021) ; 4. Novello, *et. al. J Clin Oncol* 41, no. 11 (2023)

Ivonescimab Phase III Trials – Expected Short-Term Catalysts

Summit therapeutics

HARMONi™

Last Patient In

Participate in Major Medical Conferences

Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024

AK112-303 Interim Analysis *Randomized Phase III Trial vs. Pembrolizumab*

AK112-301 CDE Decision Expected* & Topline Data

AK112-306 Last Patient In *1L sq-NSCLC Phase III Trial vs. Tislelizumab+chemo*

Akesobio

Head-to-Head vs. Pembrolizumab

Same Subset Patient Population

*NDA Filing by Akeso with the CDE for Marketing Approval in China, 2023

Ligufalimab

Potential FIC anti-CD47 mAb

Ligufalimab (AK117): Most Advanced CD47 mAb without RBC Hemagglutination - Provides Foundation for Superior Safety

Ligufalimab (AK117) is a human IgG4 antibody targeting CD47 with an excellent safety profile

Unique binding stereoselectivity of AK117 avoids transcellular binding



Structure analysis results were published on Journal for ImmunoTherapy of Cancer 2022;10:e005517

Eliminated Hemagglutination of Human RBC



- **Ligufalimab** does not induce hemagglutination of human RBC up to **1,050 μg/mL**
- **Magrolimab** triggers hemagglutination at as low as **1.44 μg/mL**

Ligufalimab Favorable Safety Profile in Dose Escalation Phase

- **Ligufalimab showed superior safety in Phase I clinical studies [Australia (AK117-101, FIH) and China (AK117-102)]**
- **No severe hematologic toxicities or severe hemoglobin drop observed at up to 45 mg/kg in solid tumor or lymphoma**
- **Complete elimination of RBC hemagglutination, and no need for priming dose**

Solid Tumor/Lymphoma	Ligufalimab ≥20mg/kg (TEAE)			
	20mg/kg (13)	30mg/kg (21)	45mg/kg (17)	Total (51)
Hemagglutination	0	0	0	0
Anemia	**23% (3/13)**	**14% (3/21)**	**41% (7/17)**	**25% (13/51)**
Thrombocytopenia	8% (1/13)	10% (2/21)	12% (2/17)	10% (5/51)
Hyperbilirubinemia	8% (1/13)	0	6% (1/17)	4% (2/51)
Headache	38% (5/13)	0	6% (1/17)	12% (6/51)
Fatigue	0	10% (2/21)	6% (1/17)	6% (3/51)
Fever	15% (2/13)	14% (3/21)	6% (1/17)	12% (6/51)
Infusion-related reaction	0	0	0	0

Data cutoff: Aug. 25, 2023
Data pooled from 2 trials: AK117-101 (with monotherapy and cadonilimab combination for advanced solid tumors in Australia), AK117-102 (monotherapy in advanced solid tumors and lymphomas in China)

Ligufalimab with Potential Best-In-Class Safety Profile and Superior Efficacy

A CD47 blocking antibody without RBC hemagglutination

No priming dose needed; minimal anemia in patients treated; no DLT up to 45 mg/kg

Good safety profile demonstrated in both mono and in combo with bispecific mAb and chemo

Combo with azacitidine showed promising efficacy in 1L HR-MDS and 1L unfit AML

Combo with bispecific I/O mAb and chemo showed promising efficacy signals in advanced solid tumors

Global development planned, including studies in both hematologic and solid tumors:

- Combination with azacitidine for 1L HR-MDS and 1L unfit AML
- Combination with cadonilimab or ivonescimab ± chemo, for advanced solid tumors
  e.g. HNSCC, GC, pancreatic, TNBC etc.

Ebdarokimab (IL-12/IL-23) NDA Filed in August 2023

1st IL-12/IL-23 blocking medicine developed in China filed for market approval

Ebdarokimab
IL-12/IL-23, AK101
NDA accepted by CDE in Aug 2023

- **Ebdarokimab targets both IL-12&IL-23**
- **Indication filed: Moderate-to-severe psoriasis**

Excellent safety and efficacy results Sustained benefits over long time use

Phase III results published at 2023 EADV

EA DV CONGRESS

Key results	Ebdarokimab
PASI75(%)	79%*
sPGA0/1(%)	64%*

** : Clinical trial results of AK101-201, AK101-301, AK101-302 and AK101-303 published at 2023 EADV*

- **Competitive advantage**
  Convenient dosing regimen:
  Only **4** times dosing per year
  (5 times in the 1st year)

Huge unmet medical needs in China

6.70 million
Psoriasis patients in China

$9.5 billion USD
Market size expected in 2030
CAGR up to **27%**

Source: Frost & Sullivan, *2017-2030 (Estimated) China Psoriasis Drug Market*

Ebronucimab (PCSK9) NDA Filed in June 2023

Ebronucimab
PCSK9, AK102
NDA accepted by CDE in June 2023

Two indications filed

- Primary hypercholesterolemia and mixed hyperlipidemia
- Heterozygous familial hypercholesterolemia (HeFH)

Excellent safety and efficacy results Sustained benefits over long time use

Competitive advantage

3 Dosing regimens
All show significant reduction from baseline

LDL-C level significantly lowered

65+%*
In each cycle

Q6W
Higher compliance

**: Clinical trial results of AK102-201, AK102-301, AK102-302 and AK102-303*

Huge unmet medical needs in China

110 million
Hypercholesterolemia patients

$1.34 billion
PCSK9 market

Source: 2023-2030 (Estimated) China PCSK9 Market , Frost & Sullivan

Key Near-Term (2024 – Early 2025) Milestones

NDA/sNDA Approval

Ivonescimab + chemo
- EGFR-TKI progressed nsq-NSCLC

Ebronucimab (PCSK9)
- Hypercholesterolemia
- Heterozygous familial hypercholesterolemia

Ebdarokimab (IL-12/IL-23)
- Moderate-to-severe psoriasis

Penpulimab + chemo
- 1L NPC

NDA/sNDA Submission

Ivonescimab
- 1L PD-L1（+）NSCLC, vs. pembrolizumab

Cadonilimab + chemo
- 1L GC/GEJC

Cadonilimab + chemo ± bevacizumab
- 1L Cervical Cancer

Gumokimab (IL-17)
- Moderate-to-severe psoriasis

Potential Phase III Initiation

Cadonilimab
- 2 Phase III trials

Ivonescimab
- 2 Phase III trials

Manfidokimab (IL-4R)
- 1 Phase III trial

Phase III Data Readouts

Cadonilimab + chemo
- 1L GC/GEJC

Cadonilimab + chemo ± bevacizumab
- 1L Cervical Cancer

Ivonescimab
- 1L PD-L1 (+) NSCLC, vs. pembrolizumab

Ivonescimab + chemo
- 2L+ EGFR-TKI progressed nsq-NSCLC

Gumokimab (IL-17)
- Moderate-to-severe psoriasis

Phase III Enrolment Completion

Cadonilimab
- Adjuvant therapy for HCC

Ivonescimab + chemo
- 1L sq-NSCLC, vs. tislelizumab + chemo
- 2L+ 3rd gen EGFR-TKI progressed nsq-NSCLC

Gumokimab (IL-17)
- Ankylosing spondylitis

POC Readouts

Cadonilimab combo studies

Ivonescimab combo studies

Ligufalimab combo studies

AK127 (TIGIT) combo studies

AK109 (VEGFR2) combo studies

And more…

Pipeline Advancement

Pipeline advancing to Phase II
- AK129 (PD-1/LAG3)
- AK130 (TIGIT/TGFβ)

First-in-human assets
- ADC
- Neurodegenerative diseases
- TME macrophage modulator And more …

Akeso Pipeline with 3 Marketed Drugs and 80+ IND Clearances



50+
Innovative assets, covering oncology, immunology, CNS and metabolic diseases

19
Clinical-stage pipeline

6+
potentially first-in-class bispecific antibodies

Anniko® (Penpulimab)
开坦尼® (Cadonilimab)

3 Marketed innovative biologics

Boxed programs are licensed or partnered. Milestone payments, sales royalties, and licensing revenues are expected according to the licensing agreements.

Clinical Studies and Commercialization Supported by In-House cGMP Manufacturing Facilities

Zhongshan National Health Park

3,500L
Running capacity

The first central integrated control biopharmaceutical flexible factory based on GE Healthcare FlexFactory™ in South China

Zhongshan Cuiheng - Akeso Bay Science &Technology Park

14,500L
Running capacity

4x10,000L
Stainless Steel Tank
Under validation
(will be operated in 2024)

Guangzhou Knowledge City

36,000L
Running capacity

54,000L operating capacity

160,000L total planning capacity

Akesobio

Q&A

CONTACT US:
ir@akesobio.com